Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).
暂无分享,去创建一个
H. Scher | Yipeng Wang | M. Landers | E. Winquist | G. Attard | A. Allan | R. Graf | A. Jendrisak | R. Dittamore | E. Barnett | A. Jayaram | J. Schonhoft